December 1 marks the opening of abstract submissions to the 2012 International AIDS Conference, which will be held in Washington DC in July. Original contributions to the field in the following scientific tracks will be accepted: Track A: Basic Science Track B: Clinical Science Track C: Epidemiology and Prevention Science Track D: Social Science, Human […]
The Global Fund to Fight AIDS, Malaria and Tuberculosis will not be issuing any new grants until 2014, according to an article by the Associated Press. The multilateral organization issued a press release Wednesday to announce a new strategy “to contribute substantially to international goals by saving 10 million lives and preventing 140-180 million new […]
Another arm of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial has been discontinued, the National Institute of Allergy and Infectious Diseases at the National Institutes of Health announced Friday. The Data Safety Monitoring Board (DSMB) recommended the discontinuation of the daily one percent tenofovir vaginal gel arm of the study during […]
On Monday the Joint United Nations Program on HIV/AIDS (UNAIDS) released a new report on the state of global AIDS, which shows that nearly half of people living with HIV/AIDS who qualify for treatment are receiving it. The 2011 UNAIDS World AIDS Day Report estimates that 6.6 million of the estimated 14.2 million people eligible […]
The following “What We’re Reading” collection is a compilation of recent articles making headlines in HIV and TB news. TB Detector Would Ferret out Disease Faster: This article from the Globe and Mail describes a tuberculosis detection device currently in development by researchers in India that works much like a Breathalyzer. The envisioned “electronic nose” […]
The Scientific Advisory Board (SAB) of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program met in September to discuss the results of the HIV Prevention Trials Network (HPTN) 052 trial, which found that individuals with HIV infection who were given immediate antiretroviral therapy (ART) were 96 percent less likely to transmit the virus […]
The TB Alliance announced Tuesday that it has enlisted the help of the National Institute of Allergy and Infectious Diseases (NIAID) AIDS Clinical Trial Group (ACTG) to help complete testing of a potentially shorter tuberculosis treatment regimen utilizing an antibiotic not currently registered to treat TB – moxifloxacin.
Dr. Mean Chhi Vun, director of Cambodia’s National Center for HIV/AIDS, Dermatology and STDs (NCHADS), offered an exciting progress report to the TB/HIV Working Group of the Stop TB Partnership at their meeting last week in Beijing, including representatives from tuberculosis (TB) and HIV programs in China and elsewhere in the Pacific region…
Young investigators and Fogarty students presented select posters on global health at a special gallery during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Boston last month. The event was sponsored by the National Insitutes of Health Office of AIDS Research, the Accordia Global Health Foundation and the IDSA Education and Research Foundation. In this video interview, Sten Vermund, MD, PhD, director of the Institute for Global Health at Vanderbilt University, discusses one of the student “highlights” of the evening – Krutika Kuppalli, MD, from the University of California, San Diego – and her research on HIV and leptospirosis in Chenai, India.
In the sixth in a series of debates about the world’s HIV response hosted by the World Bank and USAID, physician-scientists debated how best to transform the exciting results from the HPTN) 052 study, which demonstrated that those with HIV infection who received immediate treatment with antiretroviral therapy (ART) were 96 percent less likely to transmit HIV to their uninfected sexual partners than those whose treatment was delayed. The panelists were tasked with debating not only how to apply treatment as prevention (TasP) quickly, and how to add it to the combination prevention tool kit effectively, but more so whether or not it makes sense to have countries spend a majority of what is likely to be a flat or declining HIV prevention budget on TasP.